A detailed history of Prosperity Consulting Group, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Prosperity Consulting Group, LLC holds 11,410 shares of BMY stock, worth $606,897. This represents 0.05% of its overall portfolio holdings.

Number of Shares
11,410
Previous 8,186 39.38%
Holding current value
$606,897
Previous $339,000 74.04%
% of portfolio
0.05%
Previous 0.05%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 15, 2024

BUY
$39.66 - $51.75 $127,863 - $166,842
3,224 Added 39.38%
11,410 $590,000
Q2 2024

Aug 08, 2024

SELL
$40.25 - $52.99 $104,368 - $137,403
-2,593 Reduced 24.06%
8,186 $339,000
Q1 2024

May 01, 2024

BUY
$47.98 - $54.4 $50,331 - $57,065
1,049 Added 10.78%
10,779 $584,000
Q4 2023

Feb 13, 2024

SELL
$48.48 - $57.85 $19,537 - $23,313
-403 Reduced 3.98%
9,730 $499,000
Q3 2023

Nov 13, 2023

BUY
$57.89 - $64.73 $48,338 - $54,049
835 Added 8.98%
10,133 $588,000
Q2 2023

Jul 25, 2023

SELL
$63.71 - $70.74 $59,186 - $65,717
-929 Reduced 9.08%
9,298 $594,000
Q1 2023

Apr 24, 2023

SELL
$65.71 - $74.53 $574,239 - $651,317
-8,739 Reduced 46.08%
10,227 $708,000
Q4 2022

Feb 08, 2023

BUY
$68.48 - $81.09 $2,396 - $2,838
35 Added 0.18%
18,966 $1.36 Million
Q3 2022

Oct 17, 2022

SELL
$0.13 - $76.84 $69 - $40,955
-533 Reduced 2.74%
18,931 $1.35 Million
Q2 2022

Jul 25, 2022

SELL
$72.62 - $79.98 $52,649 - $57,985
-725 Reduced 3.59%
19,464 $1.5 Million
Q1 2022

Apr 19, 2022

SELL
$61.48 - $73.72 $28,280 - $33,911
-460 Reduced 2.23%
20,189 $1.47 Million
Q4 2021

Feb 10, 2022

BUY
$53.63 - $62.52 $1.11 Million - $1.29 Million
20,649 New
20,649 $1.34 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $113B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Prosperity Consulting Group, LLC Portfolio

Follow Prosperity Consulting Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prosperity Consulting Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prosperity Consulting Group, LLC with notifications on news.